Registry of Patients With Plasma Cell Disorders (Registry PCD)
The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:
- The incidence of plasma cell disorders both before and after malignancy
- Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
- Progression free survival (PFS)
- overall survival
- factors influencing overall survival, progression-free survival, and time to progression
- Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.
- genetic characteristics of plasma cell disorder
- cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Chutima Kunacheewa, MD
- Phone Number: 66896790959
- Email: chutima.kua@mahidol.ac.th
Study Contact Backup
- Name: Weerapat Owatthanapanich, MD
- Phone Number: 66891081983
- Email: weerapat.owa@mahidol.ac.th
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014
- Aged 18 years and above
Exclusion Criteria:
- insufficient data needed for analysis
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
register the plasma cell disorder patients
Time Frame: 10 years
|
register the plasma cell disorder patients
|
10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
incidence of plasma cell disorders
Time Frame: 10 years
|
incidence of plasma cell disorders both before and after malignancy
|
10 years
|
|
Time to progression
Time Frame: 10 years
|
- Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)
|
10 years
|
|
Progression free survival
Time Frame: 10 years
|
Progression free survival
|
10 years
|
|
overall survival
Time Frame: 10 years
|
overall survival
|
10 years
|
|
influencing factors
Time Frame: 10 years
|
factors influencing overall survival, progression-free survival, and time to progression
|
10 years
|
|
Symptoms and signs
Time Frame: 10 years
|
Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients
|
10 years
|
|
genetic characteristics
Time Frame: 10 years
|
genetic characteristics of plasma cell disorder
|
10 years
|
|
cost-effectiveness
Time Frame: 10 years
|
cost-effectiveness of treatment in Thailand
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 586/2564(IRB2)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.